PSMA与FDG-PET作为[177Lu]Lu-PSMA-617对比卡巴他赛治疗转移性去势抵抗性前列腺癌的预测与预后生物标志物(TheraP):一项随机、开放标签、2期试验的生物标志物分析
TheraP试验对比[177Lu]Lu-PSMA-617与卡巴他赛治疗转移性去势抵抗性前列腺癌,本分析评估PSMA-PET与FDG-PET参数作为预测和预后生物标志物。PSMA-PET SUVmean≥10者接受[177Lu]Lu-PSMA-617的PSA缓解优势显著高于SUVmean<10者(交互作用P=0.039)。FDG-PET MTV≥200 mL与较低缓解率相关(OR 0.44,P=0.035)。
要点
- PSMA-PET SUVmean≥10预测[177Lu]Lu-PSMA-617较卡巴他赛的PSA缓解优势更高(交互作用P=0.039)。
- FDG-PET MTV≥200 mL者无论随机分组如何,PSA缓解率均较低(OR 0.44,P=0.035)。
- 定量PET参数需专用软件,多数诊所尚未常规可用。
核心结论
- 在转移性去势抵抗性前列腺癌男性中,PSMA-PET SUVmean可预测[177Lu]Lu-PSMA-617较卡巴他赛更可能获得有利缓解。
- FDG-PET MTV高与较低缓解相关,无论随机分配的治疗如何,需进一步研究治疗强化。
- 本分析的优势是在多中心随机对照试验中验证了预设切点。
研究设计与样本
- TheraP为多中心、开放标签、随机2期试验,自澳大利亚11家医院招募多西他赛治疗后适合卡巴他赛的转移性去势抵抗性前列腺癌男性。
- 2018年2月6日至2019年9月3日随机分配200例,卡巴他赛组101例,[177Lu]Lu-PSMA-617组99例。
- 卡巴他赛20 mg/m2静脉每3周一次最多10周期;[177Lu]Lu-PSMA-617 6.0-8.5 GBq静脉每6周一次最多6周期。
- 分析为意向性治疗,使用逻辑回归;数据截止2020年7月20日中位随访18.4个月(IQR 12.8-21.8)。
主要发现
- [177Lu]Lu-PSMA-617组99例中35例(35%)与卡巴他赛组101例中30例(30%)为高PSMA摄取(SUVmean≥10)。
- SUVmean≥10者[177Lu]Lu-PSMA-617对比卡巴他赛的PSA缓解比值比OR 12.19(95%CI 3.42-58.76),SUVmean<10者为OR 2.22(95%CI 1.11-4.51),治疗-by-SUVmean交互作用padj=0.039。
- SUVmean≥10者PSA缓解率:[177Lu]Lu-PSMA-617组35例中32例(91%,95%CI 76-98) vs 卡巴他赛组30例中14例(47%,95%CI 29-65)。
- SUVmean<10者PSA缓解率:[177Lu]Lu-PSMA-617组64例中33例(52%,95%CI 39-64) vs 卡巴他赛组71例中23例(32%,95%CI 22-45)。
- FDG-PET MTV≥200 mL者两组合计PSA缓解率60例中23例(38%,95%CI 26-52) vs MTV<200 mL者140例中79例(56%,95%CI 48-65),OR 0.44(95%CI 0.23-0.84),padj=0.035。
关键数值与推荐
- PSMA-PET SUVmean≥10为预设切点,作为[177Lu]Lu-PSMA-617对比卡巴他赛缓解的预测生物标志物。
- FDG-PET MTV≥200 mL为预设切点,作为预后生物标志物。
临床怎么用
- 作者认为PSMA-PET SUVmean可指导[177Lu]Lu-PSMA-617的优化使用。
- 作者指出FDG-PET MTV高与较低缓解相关,需进一步研究治疗强化。
- 作者指出所用定量PET参数需专用软件,多数诊所尚未常规可用。
局限性
- 所用定量PET参数需专用软件,多数诊所尚未常规可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rate and progression-free survival compared with cabazitaxel in men with metastatic castration-resistant prostate cancer. In this study, we aimed to analyse gallium-68 [68Ga]Ga-PSMA-11 PET (PSMA-PET) and 2-[18F]fluoro-2-deoxy-D-glucose PET (FDG-PET) imaging parameters as predictive and prognostic biomarkers in this patient population. METHODS: TheraP was a multicentre, open-label, randomised phase 2 trial that recruited men with metastatic castration-resistant prostate cancer after treatment with docetaxel who were suitable for cabazitaxel from 11 hospitals in Australia. Participants were required to be 18 years old or older; have adequate haematological, renal, and liver function; and an Eastern Cooperative Oncology Group performance status of 0-2. Participants were randomly assigned (1:1) using a centralised system using minimisation with a random component and that stratified patients by disease burden, previous treatment with enzalutamide or abiraterone, and study site. Patients were either given cabazitaxel (20 mg/m2 intravenously every 3 weeks for up to ten cycles) or [177Lu]Lu-PSMA-617 (6·0-8·5 GBq intravenously every 6 weeks for up to six cycles). The primary study endpoint, analysed previously, was PSA response rate. The prespecified tertiary study endpoint was association between total tumour quantitative parameters on PSMA-PET, FDG-PET, and baseline characteristics with clinical outcomes. A SUVmean of 10 or higher on PSMA-PET was evaluated as a predictive biomarker for response to [177Lu]Lu-PSMA-617 versus cabazitaxel. A metabolic tumour volume (MTV) of 200 mL or higher on FDG-PET was tested as a prognostic biomarker. Both cutoff points were prespecified. The analysis was intention-to-treat, using logistic regression. This trial is registered with ClinicalTrials.gov, NCT03392428. FINDINGS: 200 patients were randomly assigned between Feb 6, 2018, and Sept 3, 2019. 101 men were assigned to the cabazitaxel group and 99 were assigned to the [177Lu]Lu-PSMA-617 group. The median follow-up at data cutoff of July 20, 2020, was 18·4 months (IQR 12·8-21·8). 35 (35%) of 99 men who were assigned [177Lu]Lu-PSMA-617 and 30 (30%) of 101 men who were assigned cabazitaxel had high PSMA uptake (SUVmean of ≥10). Odds of PSA response to [177Lu]Lu-PSMA-617 versus cabazitaxel were significantly higher for men with SUVmean of 10 or higher compared with those with SUVmean of less than 10 (odds ratio [OR] 12·19 [95% CI 3·42-58·76] vs 2·22 [1·11-4·51]; padj=0·039 for treatment-by-SUVmean interaction). PSA response rate for [177Lu]Lu-PSMA-617 compared with cabazitaxel was 32 (91% [95% CI 76-98]) of 35 men versus 14 (47% [29-65]) of 30 men in patients with SUVmean of 10 or higher, and 33 (52% [39-64]) of 64 men versus 23 (32% [22-45]) of 71 men in those with SUVmean of less than 10. High-volume disease on FDG-PET (MTV ≥200 mL) was seen in 30 (30%) of 99 men who were assigned [177Lu]Lu-PSMA-617 and 30 (30%) of 101 men who were assigned cabazitaxel. PSA response rate for both treatment groups combined for FDG-PET MTV of 200 mL or higher versus FDG-PET MTV of less than 200 mL was 23 (38% [95% CI 26-52]) of 60 men versus 79 (56% [48-65]) of 140 men (OR 0·44, 95% CI 0·23-0·84; padj=0·035). INTERPRETATION: In men with metastatic castration-resistant prostate cancer, PSMA-PET SUVmean was predictive of higher likelihood of favourable response to [177Lu]Lu-PSMA-617 than cabazitaxel, which provides guidance for optimal [177Lu]Lu-PSMA-617 use. High FDG-PET MTV was associated with lower responses regardless of randomly assigned treatment, warranting further research for treatment intensification. A strength of this analysis is the validation of pre-specified cutpoints within a multicentre, randomised, controlled trial. Quantitative PET parameters used, however, require specialised software and are not yet routinely available in most clinics. FUNDING: Prostate Cancer Foundation of Australia, Endocyte (a Novartis Company), Australian Nuclear Science and Technology Organisation, Movember Foundation, It's a Bloke Thing, CAN4CANCER, The Distinguished Gentleman's Ride.
引用
- Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022. PMID: 36261050. doi:10.1016/S1470-2045(22)00605-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。